128 related articles for article (PubMed ID: 1680941)
1. [The present and the future of tumor markers].
Nozawa S
Nihon Sanka Fujinka Gakkai Zasshi; 1991 Aug; 43(8):883-9. PubMed ID: 1680941
[TBL] [Abstract][Full Text] [Related]
2. [Tumor markers of ovarian cancer].
Nozawa S
Rinsho Byori; 1992 Apr; 40(4):349-53. PubMed ID: 1593759
[TBL] [Abstract][Full Text] [Related]
3. [Clinical usefulness of tumor markers associated with pancreatic cancer].
Watanabe H; Kawakami H; Yamakawa O; Satomura Y; Ohta H; Motoo Y; Okai T; Sawabu N
Rinsho Byori; 1994 Feb; 42(2):127-38. PubMed ID: 7908065
[TBL] [Abstract][Full Text] [Related]
4. Combination assay of urinary beta-core fragment of human chorionic gonadotropin with serum tumor markers in gynecologic cancers.
Kinugasa M; Nishimura R; Koizumi T; Morisue K; Higashida T; Natazuka T; Nakagawa T; Isobe T; Baba S; Hasegawa K
Jpn J Cancer Res; 1995 Aug; 86(8):783-9. PubMed ID: 7559103
[TBL] [Abstract][Full Text] [Related]
5. [Diagnostic value of serological tumor marker tests in patients with ovarian cancer].
Kobayashi H; Sumimoto K; Terao T; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Oct; 41(10):1501-6. PubMed ID: 2573640
[TBL] [Abstract][Full Text] [Related]
6. [Clinical usefulness of the combination assay of CA 125, SLX, and CA 72-4 in patients with ovarian cancer].
Kobayashi H; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Nov; 41(11):1731-5. PubMed ID: 2574209
[TBL] [Abstract][Full Text] [Related]
7. [Diagnosis and follow-up of ovarian cancer by a combination assay of serum sialyl SSEA-1 antigen and CA125 levels].
Iwanari O; Miyako J; Date Y; Moriyama M; Yoshino N; Kijima S; Nakayama S; Ryuhkoh K; Moriyama M; Hata T
Nihon Gan Chiryo Gakkai Shi; 1989 Jun; 24(6):1256-60. PubMed ID: 2571650
[TBL] [Abstract][Full Text] [Related]
8. [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for sialyl TN antigen: (2). Evaluation of clinical significance. STN Study Group].
Imura H; Mori T; Ohkura H; Ishii M; Ariyoshi H; Endo J; Kitao M; Takeda I; Kobayashi H; Inoue M
Gan To Kagaku Ryoho; 1989 Sep; 16(9):3221-30. PubMed ID: 2571323
[TBL] [Abstract][Full Text] [Related]
9. Urinary human chorionic gonadotropin free beta-subunit and beta-core fragment: a new marker of gynecological cancers.
Cole LA; Wang YX; Elliott M; Latif M; Chambers JT; Chambers SK; Schwartz PE
Cancer Res; 1988 Mar; 48(5):1356-60. PubMed ID: 3342414
[TBL] [Abstract][Full Text] [Related]
10. [Clinical evaluation of serum CA130 in patients with lung cancer].
Matsubara Y; Shiota T; Ishida H; Hanawa T; Yagi K; Kosaba S; Hatakenaka R; Funatsu T; Ikeda S
Nihon Gan Chiryo Gakkai Shi; 1989 Aug; 24(8):1557-65. PubMed ID: 2572655
[TBL] [Abstract][Full Text] [Related]
11. [Clinical value of a new serum tumor marker CA602 in ovarian cancers].
Suzuki M; Sekiguchi I; Ohwada M; Aida I; Tamada T
Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1454-60. PubMed ID: 2170549
[TBL] [Abstract][Full Text] [Related]
12. [Carbohydrate antigens as tumor marker].
Ohkura H
Nihon Geka Gakkai Zasshi; 1996 Feb; 97(2):145-51. PubMed ID: 8632743
[TBL] [Abstract][Full Text] [Related]
13. [Field trial for the early detection of patients with ovarian cancer].
Kobayashi H; Terao T
Rinsho Byori; 1992 Feb; 40(2):139-45. PubMed ID: 1374818
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluations of the tumor marker sialyl SSEA-1 antigen for clinical gynecological disease.
Iwanari O; Miyako J; Date Y; Nakayama S; Kijima S; Moriyama M; Karino K; Endoh J; Kitao M
Gynecol Obstet Invest; 1990; 29(3):214-8. PubMed ID: 1972688
[TBL] [Abstract][Full Text] [Related]
15. [Assessment of urinary beta-core fragment of hCG as a tumor marker of cervical cancer].
Kinugasa M; Nishimura R; Hasegawa K; Okamura M; Kimura A; Ohtsu F; Takeuchi K
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Feb; 44(2):188-94. PubMed ID: 1545171
[TBL] [Abstract][Full Text] [Related]
16. [Clinical evaluation of serum CA-50 and CA 19-9 in gynecological tumors].
Suzuki M; Ohwada M; Tamada T; Sakurabayashi I; Kawai T
Rinsho Byori; 1989 Jul; 37(7):784-8. PubMed ID: 2558243
[TBL] [Abstract][Full Text] [Related]
17. [Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases].
Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M
Gan To Kagaku Ryoho; 1994 May; 21(6):823-32. PubMed ID: 8185340
[TBL] [Abstract][Full Text] [Related]
18. Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment.
Badgwell D; Lu Z; Cole L; Fritsche H; Atkinson EN; Somers E; Allard J; Moore RG; Lu KH; Bast RC
Gynecol Oncol; 2007 Sep; 106(3):490-7. PubMed ID: 17532030
[TBL] [Abstract][Full Text] [Related]
19. Urinary gonadotropin fragment, a new tumor marker. II. Differentiating a benign from a malignant pelvic mass.
Cole LA; Nam JH; Chambers JT; Schwartz PE
Gynecol Oncol; 1990 Mar; 36(3):391-4. PubMed ID: 2318450
[TBL] [Abstract][Full Text] [Related]
20. [Clinical significance of serum sialyl Tn antigen in patients with gynecological cancer. STN Study Group].
Noda K; Shiota M; Tanizawa O; Inoue M; Tenjin Y; Sugishita T; Yakushiji M; Miyoshi T; Nozawa S; Sakuma T
Gan To Kagaku Ryoho; 1991 Jul; 18(8):1287-96. PubMed ID: 2069400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
